Xidian Pharmaceutical announced that the company recently received the “Drug Supplement Application Approval Notice” for potassium chloride granules issued by the State Drug Administration. The drug's specification is 1.5 g of potassium chloride per bag. It is a chemical drug. The license holder that approved its marketing license was changed from Suzhou Lanco Biotechnology Co., Ltd. to the company. The drug approval number remained unchanged, and there were no changes in production sites, prescriptions, production processes, quality standards, etc. Potassium chloride granules are mainly used to treat and prevent hypokalemia. The approval of this product has enriched the company's product line, and there is uncertainty about its subsequent sales.

Xidian Pharmaceutical announced that the company recently received the “Drug Supplement Application Approval Notice” for potassium chloride granules issued by the State Drug Administration. The drug's specification is 1.5 g of potassium chloride per bag. It is a chemical drug. The license holder that approved its marketing license was changed from Suzhou Lanco Biotechnology Co., Ltd. to the company. The drug approval number remained unchanged, and there were no changes in production sites, prescriptions, production processes, quality standards, etc. Potassium chloride granules are mainly used to treat and prevent hypokalemia. The approval of this product has enriched the company's product line, and there is uncertainty about its subsequent sales.